Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 27 | 2025 | 846 | 6.960 |
Why?
|
| Kidney Failure, Chronic | 4 | 2024 | 937 | 1.400 |
Why?
|
| Fatigue | 4 | 2023 | 192 | 1.060 |
Why?
|
| Sertraline | 4 | 2020 | 45 | 1.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2026 | 1444 | 1.040 |
Why?
|
| Antidepressive Agents | 4 | 2025 | 318 | 0.960 |
Why?
|
| Glomerular Filtration Rate | 5 | 2025 | 568 | 0.930 |
Why?
|
| Hypertension | 3 | 2022 | 1347 | 0.860 |
Why?
|
| Forearm | 1 | 2024 | 39 | 0.860 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2024 | 86 | 0.800 |
Why?
|
| Diuretics | 2 | 2022 | 157 | 0.800 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2023 | 57 | 0.770 |
Why?
|
| Angioedema | 1 | 2023 | 21 | 0.770 |
Why?
|
| Veterans | 3 | 2023 | 1753 | 0.760 |
Why?
|
| Renal Dialysis | 4 | 2024 | 949 | 0.750 |
Why?
|
| Renal Replacement Therapy | 2 | 2023 | 165 | 0.730 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 514 | 0.720 |
Why?
|
| Hyperkalemia | 1 | 2023 | 69 | 0.720 |
Why?
|
| Depression | 4 | 2025 | 1310 | 0.690 |
Why?
|
| Acute Kidney Injury | 3 | 2023 | 700 | 0.650 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 265 | 0.640 |
Why?
|
| Antihypertensive Agents | 2 | 2023 | 415 | 0.570 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 112 | 0.540 |
Why?
|
| Humans | 40 | 2026 | 130556 | 0.510 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 448 | 0.510 |
Why?
|
| Quality of Life | 4 | 2023 | 2074 | 0.500 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2017 | 109 | 0.500 |
Why?
|
| Vascular Calcification | 1 | 2017 | 69 | 0.490 |
Why?
|
| Blood Pressure | 2 | 2021 | 1342 | 0.470 |
Why?
|
| Troponin T | 1 | 2017 | 255 | 0.460 |
Why?
|
| Cardiovascular Diseases | 4 | 2025 | 2101 | 0.450 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 325 | 0.430 |
Why?
|
| Atherosclerosis | 2 | 2021 | 947 | 0.420 |
Why?
|
| Hypoglycemic Agents | 4 | 2026 | 477 | 0.400 |
Why?
|
| Peptide Fragments | 1 | 2017 | 688 | 0.400 |
Why?
|
| Heart Failure | 2 | 2023 | 2326 | 0.380 |
Why?
|
| Urinalysis | 2 | 2024 | 72 | 0.370 |
Why?
|
| Proteinuria | 2 | 2024 | 108 | 0.370 |
Why?
|
| Sex Workers | 1 | 2012 | 6 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 1288 | 0.370 |
Why?
|
| Inflammation | 1 | 2019 | 1486 | 0.360 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2023 | 214 | 0.360 |
Why?
|
| Contact Tracing | 1 | 2012 | 58 | 0.350 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2012 | 95 | 0.340 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 1486 | 0.340 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 746 | 0.340 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 893 | 0.320 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 115 | 0.310 |
Why?
|
| Obesity | 1 | 2021 | 2384 | 0.310 |
Why?
|
| Disease Progression | 3 | 2023 | 2193 | 0.310 |
Why?
|
| Middle Aged | 11 | 2025 | 28416 | 0.290 |
Why?
|
| Creatinine | 4 | 2025 | 396 | 0.280 |
Why?
|
| Female | 15 | 2025 | 70427 | 0.260 |
Why?
|
| Aged | 9 | 2025 | 20900 | 0.250 |
Why?
|
| Male | 13 | 2025 | 64536 | 0.250 |
Why?
|
| Renin-Angiotensin System | 2 | 2023 | 104 | 0.230 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 1391 | 0.230 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2023 | 134 | 0.230 |
Why?
|
| Biomarkers | 3 | 2020 | 3386 | 0.230 |
Why?
|
| Survival Analysis | 2 | 2019 | 1484 | 0.220 |
Why?
|
| Specific Gravity | 1 | 2024 | 3 | 0.210 |
Why?
|
| Prognosis | 3 | 2019 | 4867 | 0.210 |
Why?
|
| Erythrocyte Transfusion | 1 | 2025 | 145 | 0.210 |
Why?
|
| Reagent Strips | 1 | 2024 | 12 | 0.210 |
Why?
|
| Adult | 9 | 2025 | 31157 | 0.210 |
Why?
|
| Arm | 1 | 2024 | 72 | 0.210 |
Why?
|
| Postoperative Care | 1 | 2025 | 294 | 0.200 |
Why?
|
| Pituitary-Adrenal System | 1 | 2023 | 33 | 0.200 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2023 | 44 | 0.190 |
Why?
|
| Surgical Procedures, Operative | 1 | 2025 | 225 | 0.190 |
Why?
|
| Prescriptions | 1 | 2023 | 44 | 0.190 |
Why?
|
| Thiazides | 1 | 2022 | 5 | 0.190 |
Why?
|
| Medication Adherence | 1 | 2026 | 335 | 0.190 |
Why?
|
| Chlorthalidone | 1 | 2022 | 25 | 0.190 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 28 | 0.180 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2022 | 35 | 0.180 |
Why?
|
| Steroids | 1 | 2023 | 169 | 0.180 |
Why?
|
| Potassium | 1 | 2023 | 265 | 0.180 |
Why?
|
| Cystatin C | 1 | 2022 | 73 | 0.180 |
Why?
|
| Retrospective Studies | 4 | 2024 | 17558 | 0.180 |
Why?
|
| Albuminuria | 2 | 2025 | 105 | 0.180 |
Why?
|
| Anemia | 1 | 2025 | 352 | 0.180 |
Why?
|
| Hematuria | 1 | 2022 | 48 | 0.170 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2021 | 18 | 0.170 |
Why?
|
| Hypotension, Orthostatic | 1 | 2021 | 20 | 0.170 |
Why?
|
| Glucosides | 1 | 2021 | 54 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6800 | 0.160 |
Why?
|
| Benzhydryl Compounds | 1 | 2021 | 77 | 0.160 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 3031 | 0.160 |
Why?
|
| Risk Factors | 5 | 2025 | 10967 | 0.150 |
Why?
|
| Body Mass Index | 2 | 2022 | 1679 | 0.140 |
Why?
|
| Risk Management | 1 | 2018 | 66 | 0.130 |
Why?
|
| United States | 5 | 2025 | 11882 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2025 | 3678 | 0.130 |
Why?
|
| Aspirin | 1 | 2018 | 214 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 456 | 0.120 |
Why?
|
| Pandemics | 1 | 2023 | 1157 | 0.120 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 401 | 0.120 |
Why?
|
| Self Report | 1 | 2019 | 551 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2022 | 2294 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2022 | 5048 | 0.110 |
Why?
|
| Cause of Death | 1 | 2017 | 502 | 0.110 |
Why?
|
| Coronary Angiography | 1 | 2017 | 453 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2019 | 12866 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1071 | 0.110 |
Why?
|
| Sex Factors | 1 | 2018 | 1340 | 0.100 |
Why?
|
| Disease Management | 1 | 2018 | 555 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2025 | 3115 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 891 | 0.100 |
Why?
|
| Comorbidity | 1 | 2018 | 1583 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1272 | 0.090 |
Why?
|
| Guatemala | 1 | 2012 | 63 | 0.090 |
Why?
|
| Sexual Partners | 1 | 2012 | 79 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 2830 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 125 | 0.090 |
Why?
|
| Kidney | 1 | 2017 | 1279 | 0.080 |
Why?
|
| Patient Preference | 1 | 2012 | 151 | 0.080 |
Why?
|
| Texas | 1 | 2017 | 3648 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2012 | 551 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2019 | 6438 | 0.070 |
Why?
|
| Time Factors | 1 | 2017 | 6215 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3752 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2025 | 235 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2025 | 286 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 89 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2025 | 328 | 0.050 |
Why?
|
| Hospitalization | 2 | 2022 | 1939 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2022 | 270 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2022 | 303 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2025 | 1060 | 0.040 |
Why?
|
| Veterans Health | 1 | 2021 | 170 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 437 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7402 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2022 | 713 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2025 | 1001 | 0.030 |
Why?
|
| Medicare | 1 | 2021 | 442 | 0.030 |
Why?
|
| Infant | 1 | 2012 | 13270 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2022 | 769 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3797 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1621 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 3320 | 0.020 |
Why?
|